Development of a risk indicator score for the identification of interstitial lung disease in patients with rheumatoid arthritis

Paulín, Francisco; Doyle, Tracy J.; Mercado, Juan Francisco; Fassola, Leandro; Fernández, Martín Tejedor; Caro, Fabián; Alberti, María Laura; Espindola, M. E. Crespo; Buschiazzo, Emilio

doi:10.1016/j.reumae.2019.05.006

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with HRCT, a predictive score based on sex, age at RA onset, RA Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28‐ESR), and the MUC5B rs35705950 risk allele had 75% sensitivity and 85% specificity for identifying RA‐ILD (15), but this tool may be difficult to apply in clinical practice. A risk score based on sex, smoking status, extraarticular manifestations, a clinical disease activity index score, and ESR had 90% sensitivity and 64% specificity for identifying RA‐ILD (49). A model based on sex, smoking status, rheumatoid factor, C‐reactive protein, and matrix metalloproteinase‐3 had a C‐index of 0.826 for accuracy to detect RA‐ILD compared with assessment by a multidisciplinary team (50).…”

Section: Introductionmentioning

confidence: 99%

Identification, Monitoring, and Management of Rheumatoid Arthritis–Associated Interstitial Lung Disease

Koduri

Solomon

2023

Arthritis & Rheumatology

View full text Add to dashboard Cite

Interstitial lung disease (ILD) is a frequent complication of rheumatoid arthritis (RA) that is associated with a significant increase in mortality. Several risk factors for the development of ILD in patients with RA have been identified, but ILD can still develop in the absence of these risk factors. Screening tools for RA‐ILD are required to facilitate early detection of RA‐ILD. Close monitoring of patients with RA‐ILD for progression is crucial to enable timely implementation of treatment strategies to improve outcomes. Patients with RA are commonly treated with immunomodulatory therapies, although their efficacy in slowing the progression of RA‐ILD remains the subject of debate. Clinical trials have shown that antifibrotic therapies slow decline in lung function in patients with progressive fibrosing ILDs, including patients with RA‐ILD. The management of patients with RA‐ILD should be based on multidisciplinary evaluation of the severity and progression of their ILD and the activity of their articular disease. Close collaboration between rheumatologists and pulmonologists is essential to optimize patient care.

show abstract

Section: Introductionmentioning

confidence: 99%